



A Public Limited Company with Share Capital of 12,672,491.25 euros  
Registered Address 49, boulevard du Général Martial Valin – 75015 Paris  
Paris Trade and Companies' Register 410 910 095

## ***SUMMARY OF ONXEO'S LIQUIDITY CONTRACT WITH KEPLER CHEUVREUX***

**January 4, 2019 – 5:45 pm CET**

Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, the following resources were listed in the liquidity account as at December 31, 2018, settlement date:

- 111,095 shares
- €176,840.71 in cash

It is recalled that when the contract was set up on December 3, 2018, the following resources had been allocated to the liquidity account:

- 87,612 shares
- €196,423.00 in cash

### **About Onxeo**

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

Onxeo is developing **AsiDNA™**, a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a unique decoy & agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the unique properties of AsiDNA™, notably its ability to oppose and even reverse tumor resistance to PARP inhibitors regardless of the genetic mutation status, and its strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. AsiDNA™ is currently being evaluated for systemic (IV) administration in advanced solid tumors in the DRIIV-1 phase I study (DNA Repair Inhibitor administered IntraVenously).

AsiDNA™ is the first compound generated from **platON™**, the Company's proprietary chemistry platform of decoy oligonucleotides dedicated to generate new innovative leads and broaden Onxeo's pipeline.

Onxeo's portfolio also includes **belinostat**, an HDAC inhibitor (epigenetics). Belinostat is already conditionally FDA-approved in the US as a 2<sup>nd</sup> line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo's partner, Spectrum Pharmaceuticals, under the name Beleodaq® (belinostat IV form).

For further information, please visit [www.onxeo.com](http://www.onxeo.com).

**Forward looking statements**

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 5.5.1.4 "Risk Factors" ("*Facteurs de Risque*") of the 2016 reference document filed with the *Autorité des marchés financiers* on April 24, 2017 under number D.17-0423, which is available on the *Autorité des marchés financiers* website ([www.amf-france.org](http://www.amf-france.org)) or on the Company's website ([www.onxeo.com](http://www.onxeo.com)).

**Onxeo**

Valerie Leroy,  
Investor Relations  
[investors@onxeo.com](mailto:investors@onxeo.com)  
+33 1 45 58 76 00

**Media Relations**

Nicolas Merigeau  
NewCap  
[onxeo@newcap.eu](mailto:onxeo@newcap.eu)  
+33 1 44 71 94 98

**Investor Relations / Strategic Communication**

Dušan Orešanský / Emmanuel Huynh  
NewCap  
[onxeo@newcap.eu](mailto:onxeo@newcap.eu)  
+33 1 44 71 94 92

**Investor Relations US**

Brian Ritchie  
LifeSci Advisors  
[britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)  
+1 212 915 2578